RxDoctor Payments Data

Adrian Nwosu

Psychiatric/Mental Health · Pearland, TXNPI 1073365821

Payments from drug & device makers

$1,814in general payments, 2019–2025

Across 29 payments — averaging $62.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$653
  • Alkermes, Inc.$364
  • E.r. Squibb & Sons, L.L.C.$288
  • Teva Pharmaceuticals USA, Inc.$227
  • Johnson & Johnson$161
  • Otsuka America Pharmaceutical, Inc.$122

What the payments were for

  • Food & beverage$1,814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814 in reported general payments places this provider in the 70th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$190,238
Medicare patients
240
Services billed
2,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate28$87,099
Risperidone OdtRisperidone13$2,553
Divalproex Sodium97$1,939
Aripiprazole21$1,917
Quetiapine Fumarate100$1,478
Risperidone82$1,437
Olanzapine OdtOlanzapine18$1,199
Olanzapine79$1,098
Sertraline Hcl90$1,078
Mirtazapine34$766
Trazodone Hcl134$732
Duloxetine Hcl23$587
Buspirone Hcl41$572
Divalproex Sodium ErDivalproex Sodium23$569
Benztropine Mesylate44$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$161$87,09928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →